CYTOKINETICS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Deficit
(In thousands, except shares)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Income (Loss) · Deficit · Deficit | |||||||
| Balance, December 31, 2022 | 94,833,975 | $94 | $1,481,590 | $(3,590) | $(1,585,994) | $(107,900) | |
| Exercise of stock options | 1,193,325 | 2 | 14,317 | — | — | 14,319 | |
| Vesting of restricted stock units | 721,216 | 1 | — | — | — | 1 | |
| Shares withheld related to net share settlement of equity awards | (262,829) | — | (10,517) | — | — | (10,517) | |
| Issuance of common stock under Employee Stock Purchase Plan | 136,065 | — | 4,140 | — | — | 4,140 | |
| Issuance of common stock under at-the-market offering, net of issuance costs | 5,016,170 | 5 | 164,228 | — | — | 164,233 | |
| Stock-based compensation | — | — | 72,065 | — | — | 72,065 | |
| Unrealized gain on available-for-sale securities, net | 3,600 | 3,600 | |||||
| Foreign currency translation adjustments | — | — | — | (20) | — | (20) | |
| Net loss | — | — | — | — | (526,244) | (526,244) | |
| Balance, December 31, 2023 | 101,637,922 | 102 | 1,725,823 | (10) | (2,112,238) | (386,323) | |
| Exercise of stock options | 2,425,991 | 3 | 48,405 | — | — | 48,408 | |
| Vesting of restricted stock units | 797,880 | — | — | — | — | — | |
| Shares withheld related to net share settlement of equity awards | (297,205) | — | (19,631) | — | — | (19,631) | |
| Issuance of common stock under Employee Stock Purchase Plan | 140,703 | — | 4,608 | — | — | 4,608 | |
| Issuance of common stock under at-the-market offering, net of issuance costs | 1,237,460 | 1 | 93,639 | — | — | 93,640 | |
| Issuance of common stock in public offering, net of issuance costs | 11,274,510 | 11 | 563,193 | — | — | 563,204 | |
| Issuance of common stock in private placement, net of issuance costs | 980,392 | 1 | 49,999 | — | — | 50,000 | |
| Exercise of warrants, net | 11,335 | — | — | — | — | — | |
| Conversion of 2026 Notes | 151 | — | — | — | — | — | |
| Stock-based compensation | — | — | 97,840 | — | — | 97,840 | |
| Unrealized gain on available-for-sale securities, net | 2,153 | 2,153 | |||||
| Foreign currency translation adjustments | — | — | — | 255 | — | 255 | |
| Net loss | — | — | — | — | (589,526) | (589,526) | |
| Balance, December 31, 2024 | 118,209,139 | 118 | 2,563,876 | 2,398 | (2,701,764) | (135,372) | |
| Exercise of stock options | 1,551,261 | 2 | 31,150 | — | — | 31,152 | |
| Vesting of restricted stock units | 883,236 | 1 | (13) | — | — | (12) | |
| Shares withheld related to net share settlement of equity awards | (51,909) | — | (2,455) | — | — | (2,455) | |
| Issuance of common stock under Employee Stock Purchase Plan | 182,639 | — | 4,827 | — | — | 4,827 | |
| Induced conversion of convertible notes | 2,168,806 | 2 | 116,670 | — | — | 116,672 | |
| Stock-based compensation | — | — | 112,286 | — | — | 112,286 | |
| Unrealized loss on available-for-sale securities, net | (990) | (990) | |||||
| Foreign currency translation adjustments | — | — | — | (778) | — | (778) | |
| Net loss | — | — | — | — | (784,955) | (784,955) | |
| Balance, December 31, 2025 | 122,943,172 | $123 | $2,826,341 | $630 | $(3,486,719) | $(659,625) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.